Evaluation of direct and indirect effects of the PPARγ agonist troglitazone on mouse endothelial cell proliferation

Satoko Kakiuchi-Kiyota, Lora L Arnold, Masanao Yokohira, Petra Koza-Taylor, Shugo Suzuki, Michelle Varney, Karen L. Pennington, Samuel Monroe Cohen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Peroxisome proliferator-activated receptor gamma (PPARγ) agonists and PPARγ/α dual agonists are used in the treatment of type 2 diabetes mellitus and hyperlipidemias. In carcinogenicity studies, some of these agonists induced hemangiomas/hemangiosarcomas in mice, but not in rats. We hypothesized that increased endothelial cell (EC) proliferation may be involved in the mechanism of PPAR agonist-induced vascular tumors in mice. We previously showed that the sarcomagenic PPARγ agonist troglitazone (TG) increased EC proliferation in brown and white adipose tissue and liver in mice at sarcomagenic doses (400 and 800 mg/kg) after four weeks of treatment. In vitro, TG had a mitogenic effect on mouse microvascular mouse ECs by increasing cell proliferation and survival. The current studies showed that treatment of mouse ECs in vitro induced alterations in proliferation pathway gene expression, especially the expression of insulin-like growth factor-1, but had no effect on mouse oxidative stress pathways. In vivo, treatment with vitamin E did not inhibit TG-induced EC proliferation in liver and adipose tissue. In addition, no hypoxic effect was detected in adipose tissue of TG-treated mice; however, TG had a minor effect on hepatocellular hypoxia. These results provide additional evidence supporting a direct mitogenic effect in the mode of action of TG-induced hemangiosarcomas in mice.

Original languageEnglish (US)
Pages (from-to)1032-1045
Number of pages14
JournalToxicologic Pathology
Volume39
Issue number7
DOIs
StatePublished - Dec 1 2011

Fingerprint

troglitazone
PPAR gamma
Endothelial cells
Cell proliferation
Endothelial Cells
Cell Proliferation
Tissue
Liver
Hemangiosarcoma
Oxidative stress
Adipose Tissue
Somatomedins
Medical problems
Vitamin E
Gene expression
Rats
Tumors
White Adipose Tissue
Brown Adipose Tissue
Hemangioma

Keywords

  • PPARγ agonist
  • endothelial cell proliferation
  • hemangiosarcoma
  • hypoxia
  • oxidative stress
  • troglitazone

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Toxicology
  • Cell Biology

Cite this

Evaluation of direct and indirect effects of the PPARγ agonist troglitazone on mouse endothelial cell proliferation. / Kakiuchi-Kiyota, Satoko; Arnold, Lora L; Yokohira, Masanao; Koza-Taylor, Petra; Suzuki, Shugo; Varney, Michelle; Pennington, Karen L.; Cohen, Samuel Monroe.

In: Toxicologic Pathology, Vol. 39, No. 7, 01.12.2011, p. 1032-1045.

Research output: Contribution to journalArticle

Kakiuchi-Kiyota, Satoko ; Arnold, Lora L ; Yokohira, Masanao ; Koza-Taylor, Petra ; Suzuki, Shugo ; Varney, Michelle ; Pennington, Karen L. ; Cohen, Samuel Monroe. / Evaluation of direct and indirect effects of the PPARγ agonist troglitazone on mouse endothelial cell proliferation. In: Toxicologic Pathology. 2011 ; Vol. 39, No. 7. pp. 1032-1045.
@article{1faf60f16f9d4ab38cf15ce818c36c16,
title = "Evaluation of direct and indirect effects of the PPARγ agonist troglitazone on mouse endothelial cell proliferation",
abstract = "Peroxisome proliferator-activated receptor gamma (PPARγ) agonists and PPARγ/α dual agonists are used in the treatment of type 2 diabetes mellitus and hyperlipidemias. In carcinogenicity studies, some of these agonists induced hemangiomas/hemangiosarcomas in mice, but not in rats. We hypothesized that increased endothelial cell (EC) proliferation may be involved in the mechanism of PPAR agonist-induced vascular tumors in mice. We previously showed that the sarcomagenic PPARγ agonist troglitazone (TG) increased EC proliferation in brown and white adipose tissue and liver in mice at sarcomagenic doses (400 and 800 mg/kg) after four weeks of treatment. In vitro, TG had a mitogenic effect on mouse microvascular mouse ECs by increasing cell proliferation and survival. The current studies showed that treatment of mouse ECs in vitro induced alterations in proliferation pathway gene expression, especially the expression of insulin-like growth factor-1, but had no effect on mouse oxidative stress pathways. In vivo, treatment with vitamin E did not inhibit TG-induced EC proliferation in liver and adipose tissue. In addition, no hypoxic effect was detected in adipose tissue of TG-treated mice; however, TG had a minor effect on hepatocellular hypoxia. These results provide additional evidence supporting a direct mitogenic effect in the mode of action of TG-induced hemangiosarcomas in mice.",
keywords = "PPARγ agonist, endothelial cell proliferation, hemangiosarcoma, hypoxia, oxidative stress, troglitazone",
author = "Satoko Kakiuchi-Kiyota and Arnold, {Lora L} and Masanao Yokohira and Petra Koza-Taylor and Shugo Suzuki and Michelle Varney and Pennington, {Karen L.} and Cohen, {Samuel Monroe}",
year = "2011",
month = "12",
day = "1",
doi = "10.1177/0192623311422080",
language = "English (US)",
volume = "39",
pages = "1032--1045",
journal = "Toxicologic Pathology",
issn = "0192-6233",
publisher = "SAGE Publications Inc.",
number = "7",

}

TY - JOUR

T1 - Evaluation of direct and indirect effects of the PPARγ agonist troglitazone on mouse endothelial cell proliferation

AU - Kakiuchi-Kiyota, Satoko

AU - Arnold, Lora L

AU - Yokohira, Masanao

AU - Koza-Taylor, Petra

AU - Suzuki, Shugo

AU - Varney, Michelle

AU - Pennington, Karen L.

AU - Cohen, Samuel Monroe

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Peroxisome proliferator-activated receptor gamma (PPARγ) agonists and PPARγ/α dual agonists are used in the treatment of type 2 diabetes mellitus and hyperlipidemias. In carcinogenicity studies, some of these agonists induced hemangiomas/hemangiosarcomas in mice, but not in rats. We hypothesized that increased endothelial cell (EC) proliferation may be involved in the mechanism of PPAR agonist-induced vascular tumors in mice. We previously showed that the sarcomagenic PPARγ agonist troglitazone (TG) increased EC proliferation in brown and white adipose tissue and liver in mice at sarcomagenic doses (400 and 800 mg/kg) after four weeks of treatment. In vitro, TG had a mitogenic effect on mouse microvascular mouse ECs by increasing cell proliferation and survival. The current studies showed that treatment of mouse ECs in vitro induced alterations in proliferation pathway gene expression, especially the expression of insulin-like growth factor-1, but had no effect on mouse oxidative stress pathways. In vivo, treatment with vitamin E did not inhibit TG-induced EC proliferation in liver and adipose tissue. In addition, no hypoxic effect was detected in adipose tissue of TG-treated mice; however, TG had a minor effect on hepatocellular hypoxia. These results provide additional evidence supporting a direct mitogenic effect in the mode of action of TG-induced hemangiosarcomas in mice.

AB - Peroxisome proliferator-activated receptor gamma (PPARγ) agonists and PPARγ/α dual agonists are used in the treatment of type 2 diabetes mellitus and hyperlipidemias. In carcinogenicity studies, some of these agonists induced hemangiomas/hemangiosarcomas in mice, but not in rats. We hypothesized that increased endothelial cell (EC) proliferation may be involved in the mechanism of PPAR agonist-induced vascular tumors in mice. We previously showed that the sarcomagenic PPARγ agonist troglitazone (TG) increased EC proliferation in brown and white adipose tissue and liver in mice at sarcomagenic doses (400 and 800 mg/kg) after four weeks of treatment. In vitro, TG had a mitogenic effect on mouse microvascular mouse ECs by increasing cell proliferation and survival. The current studies showed that treatment of mouse ECs in vitro induced alterations in proliferation pathway gene expression, especially the expression of insulin-like growth factor-1, but had no effect on mouse oxidative stress pathways. In vivo, treatment with vitamin E did not inhibit TG-induced EC proliferation in liver and adipose tissue. In addition, no hypoxic effect was detected in adipose tissue of TG-treated mice; however, TG had a minor effect on hepatocellular hypoxia. These results provide additional evidence supporting a direct mitogenic effect in the mode of action of TG-induced hemangiosarcomas in mice.

KW - PPARγ agonist

KW - endothelial cell proliferation

KW - hemangiosarcoma

KW - hypoxia

KW - oxidative stress

KW - troglitazone

UR - http://www.scopus.com/inward/record.url?scp=82355169072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82355169072&partnerID=8YFLogxK

U2 - 10.1177/0192623311422080

DO - 10.1177/0192623311422080

M3 - Article

VL - 39

SP - 1032

EP - 1045

JO - Toxicologic Pathology

JF - Toxicologic Pathology

SN - 0192-6233

IS - 7

ER -